D
+1
Hesai: Tesla 'Disdain'? Still Growing Wildly Towards the Sun
ATX continues to increase volume in shipments!
+1HESAI
Aridis Pharmaceuticals
ARDS0.00010.00% ( 0.0000 )
Aridis Pharmaceuticals (ARDS)
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 0.0001
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 0.0500
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Aridis Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Nov 6, 2023Price forecast
$2.001999900.00%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · 1 day ago, 10:42 AM
Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle
- Unusual Whales · 2 days ago, 06:03 AM
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
- prnewswire · Feb 26 at 12:02 PM
13:00 ETArna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform
- Nov 11, 2025 at 08:16 AM
Hesai: Tesla 'Disdain'? Still Growing Wildly Towards the Sun
- GlobeNewswire · Mar 19, 2025 at 11:22 AM
Acute Respiratory Distress Syndrome Market Forecast Report and Company Analysis 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun,Teva
- Unusual Whales · Dec 20, 2024 at 07:22 AM
Aridis Pharmaceuticals, Inc. provides corporate update on recent developments on Dec. 20, 2024.
Posts
View MoreBullish vs. Bearish — Last 3 Months
12 followers · 0 opinions
▲Bullish50%
50%Bearish▼